Pol Polyprotein - Pipeline Review, H1 2016

Global Markets Direct’s, ‘Pol Polyprotein - Pipeline Review, H1 2016’, provides in depth analysis on Pol Polyprotein targeted pipeline therapeutics.

The report provides comprehensive information on the Pol Polyprotein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Pol Polyprotein targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Pol Polyprotein
  
• The report reviews Pol Polyprotein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  
• The report reviews key players involved in Pol Polyprotein targeted therapeutics and enlists all their major and minor projects
  
• The report assesses Pol Polyprotein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  
• The report summarizes all the dormant and discontinued pipeline projects
  
• The report reviews latest news and deals related to Pol Polyprotein targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  
• Identify and understand the targeted therapy areas and indications for Pol Polyprotein
  
• Identify the use of drugs for target identification and drug repurposing
  
• Identify potential new clients or partners in the target demographic
  
• Develop strategic initiatives by understanding the focus areas of leading companies
  
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  
• Devise corrective measures for pipeline projects by understanding Pol Polyprotein development landscape
  
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Pol Polyprotein Overview 6
Therapeutics Development 7
Pol Polyprotein - Products under Development by Stage of Development 7
Pol Polyprotein - Products under Development by Therapy Area 8
Pol Polyprotein - Products under Development by Indication 9
Pol Polyprotein - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Pol Polyprotein - Products under Development by Companies 12
Pol Polyprotein - Products under Development by Universities/Institutes 14
Pol Polyprotein - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Pol Polyprotein - Companies Involved in Therapeutics Development 21
GeoVax Labs, Inc. 21
Inovio Pharmaceuticals, Inc. 22
Johnson & Johnson 23
Pol Polyprotein - Drug Profiles 24
GOVXB-11 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
GOVXC-11 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
GOVXC-21 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
HIV [serotype Ad26] (tetravalent) vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
HIV-1 (bivalent) vaccine - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
HIV-1 vaccine 11 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
HIV-1 vaccine 5 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
PENNVAX-B - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
PENNVAX-GP - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Pol Polyprotein - Dormant Projects 38
Pol Polyprotein - Featured News & Press Releases 39
May 18, 2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 39
Apr 14, 2016: GeoVax Awarded $1.4M NIH Grant 40
Mar 07, 2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates 40
Sep 08, 2015: Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine 41
Apr 14, 2015: GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine 42
Apr 09, 2015: GeoVax Provides Details of Presentation at World Vaccine Congress 42
Apr 01, 2015: GeoVax Provides Update on Its HIV Vaccine Program 43
Mar 16, 2015: Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases 44
Jan 06, 2015: Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV 45
Oct 29, 2014: GeoVax Presents HIV Vaccine Clinical Trial Data 46
Jul 30, 2014: GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health 47
Jan 23, 2014: GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases 47
Jan 13, 2014: GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients 48
Oct 09, 2013: GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV 49
Jan 10, 2013: GeoVax Announces Enrollment Completion For Phase I/II Clinical Trial For HIV/AIDS Therapeutic Vaccine 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by GeoVax Labs, Inc., H1 2016 21
Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 22
Pipeline by Johnson & Johnson, H1 2016 23
Dormant Projects, H1 2016 38

List of Figures

Number of Products under Development for, H1 2016 7
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Routes of Administration, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 17
Number of Products by Molecule Types, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 19